We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+132.32%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$742M
AUM Growth
+$199M
Cap. Flow
+$27.6M
Cap. Flow %
3.72%
Top 10 Hldgs %
43.53%
Holding
99
New
34
Increased
28
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$33.1M
2
RNAM
Avidity Biosciences
RNAM
+$17.6M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$14.8M
4
GUTS icon
Fractyl Health
GUTS
+$13.5M
5
BIIB icon
Biogen
BIIB
+$10.9M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$39M
2
VRNA
Verona Pharma
VRNA
+$33.9M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.5M
4
ETNB
89bio
ETNB
+$20M
5
SLNO
Soleno Therapeutics
SLNO
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
26
Verastem
VSTM
$528M
$9.21M 1.24%
+1,042,757
New +$7.76M
AVTX icon
27
Avalo Therapeutics
AVTX
$1.01B
$9.16M 1.24%
+720,922
New +$6.2M
OLMA icon
28
Olema Pharmaceuticals
OLMA
$977M
$9.14M 1.23%
+933,541
New +$5.61M
CLDX icon
29
Celldex Therapeutics
CLDX
$2.94B
$9.03M 1.22%
348,922
+150,481
+76% +$3.49M
SRRK icon
30
Scholar Rock
SRRK
$5.88B
$8.71M 1.17%
233,920
-107,090
-31% -$3.75M
VCYT icon
31
Veracyte
VCYT
$4.45B
$8.09M 1.09%
235,791
-212,704
-47% -$6.1M
SNDX icon
32
Syndax Pharmaceuticals
SNDX
$1.7B
$7.13M 0.96%
463,708
+60,744
+15% +$795K
RAPP
33
Rapport Therapeutics
RAPP
$1.96B
$6.06M 0.82%
+203,946
New +$3.64M
VRDN icon
34
Viridian Therapeutics
VRDN
$2.2B
$5.6M 0.76%
+259,509
New +$4.68M
ALKS icon
35
Alkermes
ALKS
$8.11B
$5.42M 0.73%
+180,513
New +$5.09M
TRVI icon
36
Trevi Therapeutics
TRVI
$2.57B
$5.39M 0.73%
588,789
+49,202
+9% +$369K
BBOT
37
BridgeBio Oncology
BBOT
$659M
$5.3M 0.71%
457,414
-155,979
-25% -$1.63M
ABEO icon
38
Abeona Therapeutics
ABEO
$355M
$5.25M 0.71%
994,754
+76,856
+8% +$487K
LXEO icon
39
Lexeo Therapeutics
LXEO
$338M
$5.17M 0.7%
+778,611
New +$3.77M
COGT icon
40
CALL
Cogent Biosciences
COGT
$6.76B
$5.17M 0.7%
+360,000
New +$4.27M
GLUE icon
41
Monte Rosa Therapeutics
GLUE
$1.82B
$5.15M 0.69%
+694,942
New +$3.68M
CGEN icon
42
Compugen
CGEN
$212M
$4.87M 0.66%
3,311,165
+277,286
+9% +$412K
PHVS icon
43
Pharvaris
PHVS
$2.28B
$4.59M 0.62%
+183,903
New +$4.08M
CELC icon
44
Celcuity
CELC
$4.06B
$4.38M 0.59%
+88,686
New +$3.55M
CERS icon
45
Cerus
CERS
$575M
$4.32M 0.58%
2,715,786
+227,495
+9% +$307K
CCCC icon
46
C4 Therapeutics
CCCC
$389M
$4.21M 0.57%
+1,897,383
New +$4.55M
TELA icon
47
TELA Bio
TELA
$30.3M
$4.15M 0.56%
2,782,923
+3,128
+0.1% +$5.51K
AARD
48
Aardvark Therapeutics
AARD
$116M
$4.08M 0.55%
306,912
+20,105
+7% +$227K
BCAX
49
Bicara Therapeutics
BCAX
$1.7B
$3.96M 0.53%
+250,606
New +$2.81M
BNTC icon
50
Benitec Biopharma
BNTC
$414M
$3.88M 0.52%
276,267
+23,033
+9% +$294K
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Silverarc Capital Management held 99 positions worth $742M, up 37% from $542M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $27.6M of net new capital in Q3 2025, opening 34 new positions and adding to 28 existing holdings. Its largest new stake was Abivax: 539,704 shares worth $45.8M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was UroGen Pharma, an estimated $7.99M trimmed.

  • Silverarc Capital Management's largest Q3 2025 buy was Abivax: 539,704 shares worth $45.8M.
  • Silverarc Capital Management added most to Avidity Biosciences in Q3 2025, an estimated $17.6M increase.
  • Silverarc Capital Management's biggest Q3 2025 reduction was UroGen Pharma, cutting an estimated $7.99M.
  • Silverarc Capital Management fully exited Merus in Q3 2025, selling an estimated $39M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $742M portfolio in Q3 2025.
  • Silverarc Capital Management opened 34 new positions and closed 17 in Q3 2025.
  • Silverarc Capital Management's portfolio value rose 37% quarter-over-quarter to $742M.

Based on Silverarc Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.